During the first year of treatment, donepezil delays the incidence of Alzheimer's disease in patients with cognitive deterioration. Vitamin E is not efficient;Durante el primer año de tratamiento, el donepezil retrasa la aparición de enfermedad de Alzheimer en pacientes con deterioro cognitivo. La vitamina E no es eficaz

FMC Formacion Medica Continuada en Atencion Primaria

Volumn 12, Issue 10, 2010, Pages 715-

  Vinyoles Bargallo E ^a  

^a CAP La Mina   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; APOLIPOPROTEIN E4; DONEPEZIL; PLACEBO;

ADULT; AGED; ALZHEIMER DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; MENTAL DETERIORATION; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY; NOTE; RANDOMIZED CONTROLLED TRIAL;

EID: 77950509959     PISSN: 11342072     EISSN: 15789675     Source Type: Journal    
DOI: 10.1016/S1134-2072(05)71291-3     Document Type: Article

References (2)

1. M. Sano, C. Ernesto, and R.G. Thomas A controlled trial of selegilina, alpha-tocopherol or both as treatment for Alzheimer's disease N Engl J Med 336 1997 1216 1222 (Pubitemid 27183651)
2. R.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E.G. Tangalos, and E. Kokmen Mild cognitive impairment: clinical characterization and outcome Arch Neurol 56 1999 303 308 (Pubitemid 29120227)